FDA Approves Ajovy for Migraine Prevention in Children and Teens
By Lori Solomon HealthDay Reporter
MONDAY, Aug. 11, 2025 -- The U.S. Food and Drug Administration has approved the single-dose Ajovy (fremanezumab-vfrm) injection for the preventive treatment of episodic migraine in children and adolescents.
In the United States, one in 10 children and adolescents experience migraine, a common but often underrecognized and undertreated condition that can cause missed school, academic challenges, and social disruptions.
Ajovy is the first and only calcitonin gene-related peptide antagonist approved for pediatric episodic migraine prevention and migraine prevention in adults. Ajovy is authorized for adults and children/adolescents aged 6 to 17 years and weighing at least 45 kg (99 lb). Ajovy is a 225-mg/1.5-mL single-dose injection, available in a prefilled autoinjector or syringe, and can be given by a health care professional or self-administered or administered by a parent or caregiver in the home environment.
"Pediatric migraine is a complex condition that can significantly impact a child’s daily life, from school performance to emotional well-being," Jennifer McVige, M.D., from the DENT Neurologic Institute in Buffalo, New York, said in a statement. "Having an FDA-approved treatment like Ajovy offers an important option, providing a targeted approach to preventive treatment for episodic migraine that can help reduce the frequency of attacks in younger patients and help clinicians manage this often-overlooked condition."
Approval of Ajovy was granted to Teva Pharmaceuticals.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted August 2025
Read this next
Battling Multiple Chronic Illnesses Can Double Risk Of Depression
WEDNESDAY, May 21, 2025 — Battling chronic disease really takes it out of a person, leaving them vulnerable to depression. And people with multiple long-term health...
Oral Health Linked To Migraines, Fibromyalgia
TUESDAY, May 20, 2025 — Women who don’t brush and floss frequently are more likely to suffer from migraines and fibromyalgia, a new study says. Women with the worst...
Ubrogepant (Ubrelvy) Effective Against Early Migraine Symptoms
WEDNESDAY, May 14, 2025 -- Migraines don’t just cause headaches. These attacks often are accompanied by symptoms like light and sound sensitivity, nausea, neck pain and...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.